Hoth Therapeutics, Inc. (HOTH) reported proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The company said a significant decline in Aß was seen in the Alzheimer's disease mouse model after acute treatment with HT-ALZ.
Alzheimer's disease is a neurodegenerative disease that is characterized by aggregates of amyloid ß (Aß) plaques and neurofibrillary tangles of Tau protein in the brain. HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.
Shares of Hoth Therapeutics were up 43% in pre-market trade on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.